An open label, randomized, single center trial in healthy young women, to evaluate the effects of a monophasic combined oral contraceptive (COC) containing 2.5 mg NOMAC [nomegestrol] and 1.5 mg E2 [ethinyl estradiol] on bone mineral density (BMD) compared to a monophasic COC containing 0.150 mg levonorgestrel and 0.030 mg ethinyl estradiol.

Trial Profile

An open label, randomized, single center trial in healthy young women, to evaluate the effects of a monophasic combined oral contraceptive (COC) containing 2.5 mg NOMAC [nomegestrol] and 1.5 mg E2 [ethinyl estradiol] on bone mineral density (BMD) compared to a monophasic COC containing 0.150 mg levonorgestrel and 0.030 mg ethinyl estradiol.

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Jun 2014

At a glance

  • Drugs Estradiol/nomegestrol (Primary) ; Ethinylestradiol/levonorgestrel
  • Indications Pregnancy
  • Focus Pharmacodynamics
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 16 Sep 2009 Actual end date (Jun 2009) added as reported by ClinicalTrials.gov.
    • 16 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 24 Jan 2008 The expected completion date for this trial is now 1 Aug 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top